HLA announces the creation of a new Advisory Group to support the delivery of its core mission.

The group is composed of distinguished professionals with deep knowledge of the humanitarian logistics sector, including many who have been closely involved with the work of HLA over the years. They are:

Andrew Parkes, Global Operations Manager, Malaria Consortium

Nick Murdoch, Independent Logistics & Supply Chain Consultant

Will Holden, Managing Director Emergency Logistics Team, CMILT

Martijn Blansjaar, Head of Supply and Logistics, OXFAM GB

Jane Tikhwi Muyundo, Castelbarco Capacity Building Consultants

Stuart Smith, Global Director, Humanitarian, Volga Dnepr Group

Neil Rodrigues, Director Global Supply Chain, International Medical Corps

Jarrod Goentzel, Director, MIT Humanitarian Supply Chain Lab

Michael C. Whiting, independent humanitarian logistics consultant

Ilse Larkin, independent humanitarian logistics professional and guest lecturer at University of Cranfield

John Cropper, Lead, Program Management and Humanitarian, Humentum

Frank Clary, VP Sustainability, Agility Logistics

The first meeting of the newly-constituted board took place on May 30, 2019 where they discussed among other things the draft HLA strategy, and the new ‘HLA Connect’ – which is an enhanced web platform which aims to make it less challenging for stakeholders to engage with the humanitarian logistics (HL) sector, and other related humanitarian initiatives / activities.

The group will meet remotely every two months, with the next call scheduled for the end of July.

“I am immensely pleased that HLA has now been able to launch a new advisory group to help steer the organisation through the implementation of its latest three-year strategy. HLA is extremely grateful to the members that have joined the group; they bring a broad range of expertise and wealth of experience. Their commitment to supporting the aims of the HLA and to building humanitarian logistics as a recognised sector is hugely important.” George Fenton, Chief Executive, HLA